A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The ...

An expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors ...

In patients with advanced or recurrent endometrial cancer (EC) with previous exposure to carboplatin and paclitaxel (PT), ...

Combination treatment with cadonilimab and lenvatinib can produce responses in patients with advanced endometrial cancer.

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Comorbidity burden and effectiveness of immunotherapy in patients with metastatic renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the European Commission (EC) to treat hepatocellular carcinoma (HCC), the most common type of ...

The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib ...